PRG4 (Proteoglycan 4)

Two proteins showed inverted patterns between cohorts, likely due to chemotherapy. Our findings call for further investigation into the proteins identified, warranting further validation in larger, standardized studies.

Importantly, inhibition of lipid accumulation with the fatty acid synthase inhibitor C75 reduced PRG4+ macrophage numbers, attenuated fibrosis, and suppressed lung metastasis. Together, these findings implicate long-term tamoxifen treatment as a potential risk factor for lung metastasis in ER-positive BC by disrupting the lung microenvironment, and suggest that targeting lipid metabolism may represent a therapeutic strategy to limit metastatic progression, particularly in the lung.

Our findings unveil a brain-cartilage circuit that regulates cartilage regeneration, providing valuable insights into the inherent limitations of tissue regeneration and suggesting a promising treatment strategy for enhancing cartilage regeneration.

Herein, it is described the case of a 70-year-old man affected by metastatic SCACP, treated with three different sequential therapy lines: carboplatin plus paclitaxel, epirubicin, and an off-label protocol with enzalutamide, achieving 41 months overall survival. Interestingly, SCACP demonstrated to be responsive to enzalutamide treatment, even though the patient precociously stopped the treatment due to severe toxicity. This case represents the first evidence of hormonotherapy administration in a SCACP patient, possibly providing the base for a new therapeutic opportunity for this rare malignancy.

PRG4 demonstrated antitumor activities in vivo and shows promise as an adjuvant to enhance therapeutic interventions in HCC.

The accuracies of nine- and three-protein signatures were 85.8% (area under the receiver operating characteristic curve: 0.8526) and 77.0%, respectively. The nine-protein signature may help detect breast cancer more accurately and effectively than the three-protein signature.

Furthermore, a molecular network comprising four transcription factors and 11 downstream genes was discovered. This newly identified molecular network enhances our understanding of the distinct mechanisms underlying IPF and SCC onset, and provides new insights into preventing SCC complications in patients with IPF.

The results further support the continued investigation of circulating plasma-derived EVs as biomarkers in melanoma. Furthermore, the potential of combined proteo-metabolomic signatures for differentiation between disease stages may provide valuable insights into early detection, prognosis, and personalised treatment strategies.

The selected passage showed a clear influence, especially on inflammation markers. Further experiments were warranted to explore the effects of TNFα concentration and passage in long-term stimulation.

We conclude that these unusual tumors represent a distinct category of synoviocytic neoplasia, which we term "chondroid synoviocytic neoplasm", rather than simply ordinary TGCT with cartilage. Despite potentially worrisome morphologic features, they appear to behave in at most a locally aggressive fashion.

P1/2, N=12, Not yet recruiting, Lubris Bio Pty Ltd

PRG4 represses the genesis and metastasis of osteosarcoma via inhibiting PD-L1 expression, and AdPRG4 enhances the effectiveness of anti-PD-L1 therapy.